A budget impact analysis from Jordan finds that adding subcutaneous infliximab (CT-P13 SC) to the country’s existing intravenous infliximab options could generate substantial savings for the healthcare payer across six autoimmune diseases. The modeling study, published in Cost Effectiveness and Resource Allocation, estimates that over a five-year horizon the largest savings would occur in psoriasis, psoriatic arthritis, and ankylosing spondylitis, ranging from 11.7 to 13.3 million Jordanian dinars, equivalent to roughly 16.5 to 18.7 million US dollars.
Infliximab is a biologic drug used to treat a range of immune-mediated conditions. In Jordan, management of these diseases relies heavily on intravenous formulations of infliximab, which require clinic or hospital infusion visits and carry administration-related expenses.
The researchers, led by Rimal Mousa with colleagues including Nimer S. Alkhatib, built a prevalence-based budget impact model comparing the current treatment environment, in which only intravenous infliximab originator and biosimilar products are available, with two future scenarios in which subcutaneous infliximab is introduced. The first scenario assumed total adoption of the subcutaneous formulation, while the second assumed a gradual adoption over time. The five-year time horizon allowed the team to track how budget effects would evolve as market share shifted.
Inputs for the model, including the numbers of patients eligible for infliximab originator and biosimilar therapy and the market share adoption rates, were obtained from official websites. The team conducted sensitivity analyses in Microsoft Excel to test how robust the results were to variation in key input parameters, a standard approach for identifying which assumptions drive the economic conclusions.
The pattern of savings tracked disease prevalence. Highly prevalent conditions such as psoriasis, psoriatic arthritis, and ankylosing spondylitis showed the largest absolute savings, while rheumatoid arthritis, ulcerative colitis, and Crohn’s disease showed lower savings of 2.0 to 3.1 million dinars, or 2.8 to 4.4 million US dollars, over the same period.
On a per-patient basis, the picture shifted. The highest budget impact per patient was observed in ulcerative colitis and Crohn’s disease, at approximately minus 8,814.24 dinars, or about 12,432.09 US dollars, while the lowest was in rheumatoid arthritis at minus 2,810.92 dinars, reported as roughly 3,074 US dollars in the study. These per-patient figures indicate where switching an individual from intravenous to subcutaneous therapy would free up the most payer resources.
Beyond direct drug and administration costs, the analysis suggested that conversion to the more cost-saving scenario could expand treatment access. The model projected that the number of eligible patients could increase over time, particularly in the highly prevalent conditions. The authors linked this to the cumulative effect of savings: money not spent on infusion-related expenses could, in principle, extend biologic therapy to more patients within a fixed budget.
The authors concluded that the cost-saving potential of subcutaneous infliximab, alongside benefits such as fewer hospital visits and more efficient use of healthcare personnel time, supports consideration of reimbursement for the formulation within the Jordanian healthcare system. However, they emphasized that real-world evidence is still needed to address uncertainties around comparative effectiveness, patient tolerability, and clinical acceptance of the subcutaneous route.
As a modeling study based on prevalence estimates and market share assumptions, the analysis projects hypothetical budget effects rather than measuring actual spending changes. Its conclusions apply to the Jordanian payer perspective and the specific scenarios modeled, and the sensitivity analyses were designed to probe how variations in key inputs might alter the results. The findings position subcutaneous infliximab as a potentially budget-relieving option for Jordan’s autoimmune disease treatment landscape, pending the clinical and real-world data the authors say remain necessary.
Subject of Research: Budget impact of subcutaneous infliximab for autoimmune diseases in Jordan
Article Title: Budget impact analysis of subcutaneous infliximab (CT-P13 SC) for treating autoimmune diseases in Jordan
Article References: Mousa, R., Halloush, S., Radaydeh, F., Alyami, M., Melhem, S., Balkhi, B., Kurdi, A., & Alkhatib, N. S. (2026). Budget impact analysis of subcutaneous infliximab (CT-P13 SC) for treating autoimmune diseases in Jordan. Cost Effectiveness and Resource Allocation. https://doi.org/10.1186/s12962-026-00825-x
Image Credits: AI Generated
DOI: 10.1186/s12962-026-00825-x
Keywords: infliximab, subcutaneous infliximab, CT-P13 SC, autoimmune diseases, budget impact analysis, Jordan, health economics, rheumatoid arthritis, psoriasis, inflammatory bowel disease, cost savings, biosimilars
News Source: Courtney Benton. (October 29, 2026). Subcutaneous Infliximab Could Cut Jordan’s Autoimmune Disease Treatment Costs. Scienmag.
